In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dartmouth College

www.dartmouth.edu

Latest From Dartmouth College

Deals Shaping the Medical Industry, January 2017

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in December 2016.

Deals BioPharmaceutical

Deal Watch: Bristol And Otsuka Pursue Oncolytic Virus Therapies Via Licensing Deals

Busy stretch before Christmas holidays sees two deals around oncolytic virus therapeutics, a Middle East partnership for Orexigen’s Contrave, immuno-oncology deals involving Pfizer and ElsaLys, and Roche and ImmuNext partnering to develop drugs targeting the VISTA pathway.

Deals M & A

Cardio3 BioSciences Avoiding Binary Event Risks By Adding CAR-T Candidates

Belgium’s Cardio3 BioSciences aims to apply its experience in developing cell therapies, principally a stem cell therapy for heart failure that is in Phase III trials, to other therapeutic areas, reducing its exposure to the risks of a single success or failure event.

BioPharmaceutical Belgium

US IRB approval of Collategene trial boosts AnGes

Shares in AnGes MG spiked in Tokyo after the Japanese bioventure announced its US subsidiary had received final institutional review board (IRB) approval for a planned pilot trial with the firm's lead therapeutic candidate.

Orthopedics
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register